Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3-methyl-N-(pyridin-4-ylmethyl)imidazo[1,2-a]pyrazin-8-amine is a synthetic small molecule belonging to the imidazopyrazine class of organic heterocyclic compounds. It has been identified as a ligand and inhibitor for cyclin-dependent kinase 2 (CDK2), an enzyme involved in cell cycle regulation. The compound has been structurally characterized in complex with CDK2 (PDB: 2r3h), suggesting its mechanism of action is through ATP binding site inhibition of CDK2. There are no approved therapeutic indications or clinical trials reported for this molecule; it remains an experimental research tool primarily used in structural biology and biochemical studies related to kinase inhibition[1][2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-methyl-N-(pyridin-4-ylmethyl)imidazo[1,2-a]pyrazin-8-amine.